We evaluated the activity of clarithromycin, 14-OH clarithromycin, amoxycillin, bismuth, metronidazole and ciprofloxacin against six strains of Helicobacter pylori to determine if there were differences in response to these antimicrobial agents during growth in vitro. Clarithromycin and its 14-hydroxy-metabolite exhibited an early bactericidal activity with at least a 3 log,o reduction after 2-8 h incubation. Exposure to bismuth, ciprofloxacin and metronidazole resulted in a > 3 log reduction by 24 h with the greatest decrease in viability occurring between 8 and 24 h. The viable count of three strains was reduced by a 1-2 logio after 24 h exposure to amoxycillin and by a > 3 logio after 48 h.
Introduction
Helicobacter pylori is a Gram-negative bacterium associated with gastritis and peptic ulcer disease (Marshall & Warren, 1984) . A variety of antimicrobial regimens are used in combination with standard anti-ulcer medications in an effort to eradicate H. pylori, thereby reducing the frequency of relapse (Hentschel et al., 1993) . Nevertheless, a large proportion of patients still experience recurrence (Marshall et al., 1993) which might be explained by initial resistance, the development of resistance to antimicrobial agents (Hentschel et al., 1993) or by incomplete eradication or reinfection, of which little is known.
Microbial growth rate may play an important role in the bacterium's response to antimicrobial treatment as the susceptibility of microorganisms is known to vary with growth rate (Cozens et al., 1986) . Slowly growing organisms generally are more resistant to antimicrobial agents so activity against such organisms may enhance the agents' effectiveness in vivo. In a previous study, Millar & Pike (1992) found that of the seven different antimicrobial agents investigated for their activity against H. pylori NCTC 11637 growing in a chemostat, only amoxycillin and bismuth subcitrate were bactericidal. It was suggested that the relatively poor bactericidal activity of the other agents against slow growing H. pylori might be a contributing factor in limiting their clinical efficacy. Randomised clinical trials have shown clarithromycin to be efficacious in treating duodenal ulcer disease caused by H. pylori (Logan et al., 1995) and the drug is licensed for use for this indication in the USA and elsewhere. We therefore set out to compare the in-vitro activity of the drug and its active metabolite, R. K. Flamm el at.
14-OH-clarithromycin with that of ciprofloxacin, amoxycillin, metronidazole, and bismuth subcitrate by determining their MICs for six strains of H. pylori. In addition, we used a time-kill kinetic method that provided for a relatively long stationary/lag phase which allowed us to investigate the activity of each drug on these organisms during both their slow and rapid growth phases.
Materials and methods

Strains
We selected H. pylori 2723, H. pylori 2758, H. pylori 2765 which had all been isolated in the United Kingdom from specimens of gastric biopsy, H. pylori 2597 which originated from the gastric antrum of an Australian patient, and H. pylori 3226 and H. pylori 4126 which had been isolated from the gastric tissue of two patients in the USA. All strains had been stored at -70°C in water containing 10% skimmed milk and 20% glycerol. When required, the frozen culture was thawed, inoculated onto Columbia base agar containing 5% sheep blood (CBA) then incubated under a microaerophilic atmosphere of 5-12% CO 2 and 5-15% oxygen generated in an anaerobic jar using a Campy-Pak (Becton-Dickenson, Cockeysville, MD, USA) for 3 days at 37°C in a humidified cabinet.
Preparation of the inoculum
Each strain was grown for approximately 48 h on CBA in a microaerophilic atmosphere as before. The culture was then suspended in physiological saline to a turbidity of a 2.0 McFarland's standard, 30 /iL of which was added to 3 mL brain heart infusion broth containing 0.1% yeast extract and 10% heat inactivated horse serum in a 25 cm 2 tissue culture flask (T-25 flask; Costa Corporation, Cambridge, MA, USA). This resulted in a starting inoculum of approximately 10 6 cfu/mL.
Determination of MICs
MICs of amoxycillin, metronidazole, bismuth subcitrate, ciprofloxacin, clarithromycin and its 14-hydroxymetabolite (Abbott Laboratories, IL, USA) were determined by the agar dilution method of the American National Committee for Clinical Laboratory Standards (NCCLS, 1993) on Mueller-Hinton agar containing 5% lysed horse blood using an multipoint replicating device and an inoculum of approximately 1 x 10*cfu/spot that had been prepared by suspending fresh growth from CBA in physiological saline (Hardy et al., 1988) .
Determination of kill kinetics
Each strain of H. pylori was exposed to 8 x MIC of each antimicrobial agent except for the 14-OH clarithromycin which is in short supply being only produced in vivo. Only H. pylori 2597 was exposed to this substance. Each of the other drugs was tested at pH 7.2-7.4, the initial pH of the broth, and at pH 8.0 achieved by adding 0.1 M NaOH to offset the effect of increased CO 2 in the atmosphere. In addition, the effect of low pH on kill kinetics was assessed by lowering the pH to 6.5 by adding 0.1 M HC1. H. pylori 2597 was exposed to the 14-OH clarithromycin only at pH 8.0.
The flasks were placed in an anaerobe jar and shaken gently at 37°C under a microaerophilic atmosphere generated as before. A sample of 300/iL was removed at each time and two aliquots of 100/iL were inoculated directly onto two CBA plates. The remaining 100 /iL was diluted decimally in physiological saline, and 100 /iL of each dilution was plated onto CBA. Viable counts were determined after incubation at 37°C for 72 h under the same microaerophilic conditions as before.
Results and discussion Clarithromycin, 14-OH clarithromycin and amoxycillin were highly active with MICs of 0.015-0.03 mg/L. Ciprofloxacin was 4-16 fold less active with MICs ranging from 0.06 to 0.5 mg/L. MICs of metronidazole were 1-2 mg/L for H. pylori 2723, H. pylori 2765, H. pylori 3226 and H. pylori 4126 and 128 mg/L for H. pylori 2597 and H. pylori 2758. Bismuth was the least active agent with MICs of 16 mg/L for each strain. MICs of clarithromycin and its hydroxy metabolite were two-fold lower at pH 7.2-7.4 than at pH 8.0 whereas those of the other agents were the same.
At 0.12 mg/L (8 x MIC), clarithromycin was the only agent to show at least a 3 log, 0 reduction in the viable counts of all strains within 2-8 h of exposure as shown in Figure 1 for H. pylori 2597. Bismuth subcitrate at 128 mg/L, ciprofloxacin at 0.48-4 mg/L and metronidazole at 8-1024 mg/L resulted in a 3 logio reduction within 24 h in the viable count of four strains with the greatest decrease in viability occurring between 8-24 h. At 0.12-0.24 mg/L, amoxycillin reduced the viable counts by 1-2 logio cfu/mL within 24 h. Twenty-four hours later, the reduction in viable counts of H. pylori 2758 and H. pylori 2765 were greater than a 3 logio reduction a reduction of 2.5-3 logio was found for H. pylori 2723, H. pylori 3226 and H. pylori 2597 and little change was noted for H. pylori 'illd. The bactericidal activity of metronidazole occurred between 8-24 h for the four strains with MICs of 1-2 mg/L. However, the viable count of H. pylori 3226 increased by 2 logio between 24 and 48 h indicating the development of resistance. A reduction of greater than 3 logio was found after the two resistant strains H. pylori 2597 and H. pylori 2758 had been exposed to 1024 mg/L metronidazole. The activity of each of the agents against H. pylori 2597 is illustrated in Figure 2 and is representative of the results found for the other strains. In this case, both clarithromycin and amoxycillin resulted in a greater than 3 logm reduction in viable counts within 8 h. The 14-hydroxy metabolite was also rapidly bactericidal against H. pylori 2597 (Figure 2) . Equivalent activities were found for each of the antimicrobial agents at pH 7.3 and 8.0 with the exception of clarithromycin which appeared less active at the lower pH (data not shown) as has been shown previously (Hardy et al., 1988) . However, even at pH 6.5, 3 mg/L clarithromycin was bactericidal within 4h against H. pylori 2597 Figure 3 ) which is a higher concentration than that required to achieve killing at pH 8.0, but is still within the concentrations achieved in blood when the drug is given at the normal dose and well below those obtained in tissue (Hardy, Guay & Jones, 1992; Gustavson et al., 1995) . The activity of clarithromycin is enhanced by its extensive distribution in tissue and by the formation of the 14 hydroxy-metabolite which, given the activity of each against H. pylori suggests that treatment might lead to the successful eradication of the organism from the gastric mucosa and, hence, a favourable outcome of treatment. Gustavson et al. (1995) showed that concentrations of 39.3, 23.1 ngjg and 25.2/ig/g clarithromycin were achieved in the gastric mucosa 2, 4 and 6 h respectively after administering 500 mg clarithromycin tds and that corresponding concentrations of the 14 hydroxy-metabolite were 3.2, 1.1, and 4.1 /ig/g respectively. Similar results were obtained whether or not clarithromycin was given alone or together with 40 mg omeprazole once daily (Logan et al., 1995) . Although the activity of the hydroxy metabolite is about half that of the parent drug and its concentrations are lower it may still contribute antibacterial activity.
Clarithromycin was not only extremely active as demonstrated by the very low MICs, but was able to kill slow growing H. pylori rapidly which might be attributed to the extremely tight binding of both the drug and its 14-hydroxy metabolite to the organism's ribosomes (Goldman et al., 1994) and may contribute to its efficacy in the treatment of peptic ulcer disease.
